TABLE 1.

Baseline characteristics of patients receiving ADIPemCis

Patient	Age at study enrolment	Gender	Baseline LDH (240–480 U/L)	Date of primary tumour diganosis	Site of primary tumour	Treatment for primary tumour	Date of metastatic disease	Site(s) of metastatic disease	Prior treatment for metastatic disease	Baseline plasma arginine (μM)	Baseline plasma citrulline (μM)	Baseline anti‐ADI‐PEG20 antibody titre	Treatment post‐progression
A	67	M	551	18/06/09	Choroidal	Enucleation	17/02/15	Liver	Ipilimumab, interferon‐alpha, pembrolizumab	43.4	31.3	1	Palliative care
B	37	F	294	21/08/14	Choroidal	Enucleation	11/01/16	Liver	Ipilimumab	22.3	17.8	0	Pembrolizumab
C	60	M	344	01/10/10	Choroidal	Enucleation	29/01/16	Liver, lung, bone, retroperitoneal, adrenal	Ipilimumab	81.8	38.2	0	Pembrolizumab, temozolomide
D	61	M	420	08/03/13	Choroidal	Enucleation	06/05/15	Liver	Ipilimumab	56.4	34.8	2	Pembrolizumab
E	35	F	5052	19/04/12	Choroidal	Plaque brachytherapy	18/04/16	Liver	Ipilimumab, pembrolizumab, AKT inhibitor*, interferon‐alpha, selumetinib with vistusertib*	42.2	10.5	2	Palliative care
F	53	F	1248	13/03/14	Choroidal	Plaque brachytherapy	13/04/14	Liver	None	n/a	n/a	n/a	Ipilimumab, pembrolizumab
G	41	F	1696	01/01/13	Choroidal	Plaque brachytherapy	01/05/15	Liver, lung	Ipilimumab, pembrolizumab, hepatic melphalan	57.9	26.8	0	Palliative care
H	73	F	536	14/06/12	Choroidal	Plaque brachytherapy followed by enucleation	30/10/15	Liver, lung, bone	None	99.1	34.2	0	Pembrolizumab, ipilimumab, temozolomide
I	79	F	860	08/12/11	Choroidal	Plaque brachytherapy	09/04/15	Liver, bone, retroperitoneal	Ipilimumab, interferon‐alpha	109	32.9	0	Pembrolizumab, temozolomide
J	62	F	1077	06/02/09	Choroidal	Plaque brachytherapy	17/07/15	Liver, retroperitoneal, subcutaneous	Ipilimumab	60.4	18.7	2	Pembrolizumab, temozolomide

Note: Treatments received through phase 1 clinical trials are indicated with an asterisk.

Abbreviations: ADI‐PEG20, pegylated arginine deiminase; F, female; LDH, lactate dehydrogenase; M, male.